What happened: UK health advisers are expected to recommend prostate cancer screening only for men aged 45 to 61 who carry BRCA1 or BRCA2 genetic variants. Routine screening will not be offered to the wider male population.
Why it matters:
- Screening will focus on a small group at higher genetic risk, potentially improving early detection for them.
- Most men in the UK will not have access to routine prostate cancer screening, affecting early diagnosis rates.
MNN Take: The decision reflects a targeted approach based on genetic risk, balancing benefits and resources in national health policy.
Sources: Guardian UK